As Chemotherapy-Induced Peripheral Neuropathy (CIPN) becomes increasingly prevalent worldwide and contributes to comorbidities such as diabetes, cardiovascular disease, and certain cancers, there is a growing need for safer and more effective treatments. DelveInsight reports that more than 4 pharmaceutical and biotech companies are actively developing over 5 therapeutic candidates targeting CIPN. These candidates are in various stages of clinical and preclinical development, highlighting significant innovation and dedication to tackling this pressing health challenge.
The “Chemotherapy-Induced Peripheral Neuropathy (CIPN) Pipeline Insight 2025” report by DelveInsight offers a detailed strategic assessment of the current R&D landscape. It examines clinical trial progress, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives, serving as an essential resource for researchers, healthcare investors, and decision-makers seeking insights into the evolving CIPN therapeutics market and the breakthroughs shaping its future.
Explore the Cutting-Edge Landscape of Chemotherapy Induced Peripheral Neuropathy (CIPN) Drug Development
Key Takeaways from the Chemotherapy Induced Peripheral Neuropathy (CIPN) Pipeline Report
DelveInsight’s Chemotherapy-Induced Peripheral Neuropathy (CIPN) pipeline report highlights a dynamic landscape with over 4 active companies developing more than 5 therapeutic candidates for CIPN treatment.
Key developments in 2025 include:
-
July 2025: Asahi Kasei Pharma initiated a Phase III trial in Japan for ART-123 (Recomodulin), a recombinant thrombomodulin being tested to prevent CIPN in colorectal cancer patients treated with oxaliplatin. Previous studies demonstrated promising safety and efficacy.
-
July 2025: Ananda Pharma began a Phase I pharmacokinetic study of MRX1, a cannabidiol-based therapy targeting CIPN and endometriosis, supporting potential future FDA submissions.
-
May 2025: Researchers at VCU Massey Cancer Center identified the AEG-1 gene as a critical regulator of inflammation in CIPN, suggesting that targeting this gene could offer a new approach to preventing chemotherapy-induced nerve damage.
-
January 2025: The FDA issued draft guidance for developing drugs and biologics aimed at preventing or treating CIPN in oncology patients, outlining trial design, endpoints, and regulatory expectations, signaling increased support for innovation in this field.
Leading CIPN-focused companies include Capsaicin, ATX01, and others, actively pursuing new treatments to enhance the therapeutic landscape.
Promising pipeline candidates in various stages of development include P1037 and others
Chemotherapy Induced Peripheral Neuropathy (CIPN) Overview:
Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent and challenging side effect of cancer treatment, particularly with commonly used chemotherapy drugs. It can emerge during therapy and sometimes requires dose reductions or early discontinuation, which may compromise treatment effectiveness and patient outcomes.
Although acute CIPN often improves after chemotherapy ends, some patients experience persistent or delayed-onset symptoms that can last for months. The likelihood and severity of CIPN depend on the specific chemotherapy regimen and individual patient factors. Despite improvements in cancer survival, CIPN remains a major concern for patients and healthcare providers because of its impact on daily life and the limited availability of consistently effective treatments. Early prevention and prompt management are crucial to minimizing its effects.
Download the Chemotherapy Induced Peripheral Neuropathy (CIPN) sample report to know in detail about the Chemotherapy Induced Peripheral Neuropathy (CIPN) treatment market
Chemotherapy Induced Peripheral Neuropathy (CIPN) Pipeline Analysis
The Chemotherapy Induced Peripheral Neuropathy (CIPN) pipeline insights report 2025, provides insights into:
-
Provides comprehensive insights into key companies developing therapies in the Chemotherapy Induced Peripheral Neuropathy (CIPN) Market.
-
Categorizes Chemotherapy Induced Peripheral Neuropathy (CIPN) therapeutic companies by development stage: early, mid, and late-stage.
-
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
-
Reviews emerging Chemotherapy Induced Peripheral Neuropathy (CIPN) drugs under development based on:
-
Stage of development
-
Chemotherapy Induced Peripheral Neuropathy (CIPN) Route of administration
-
Target receptor
-
Monotherapy vs. combination therapy
-
Chemotherapy Induced Peripheral Neuropathy (CIPN) Mechanism of action
-
Molecular type
-
-
Offers detailed analysis of:
-
Company-to-company and company-academia collaborations
-
Chemotherapy Induced Peripheral Neuropathy (CIPN) Licensing agreements
-
Funding and investment activities supporting future Chemotherapy Induced Peripheral Neuropathy (CIPN) market advancement.
-
Unlock key insights into emerging Chemotherapy Induced Peripheral Neuropathy (CIPN) therapies and market strategies here: https://www.delveinsight.com/report-store/chemotherapy-induced-peripheral-neuropathy-cipn-pipeline-insight??utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Chemotherapy Induced Peripheral Neuropathy (CIPN) Emerging Drugs
-
Capsaicin: Grünenthal GmbH
QUTENZA is a high-strength topical therapy that administers prescription-grade capsaicin directly to the skin in a clinical setting. It works by temporarily desensitizing the TRPV1 receptor, which plays a central role in pain signal transmission. This targeted approach allows a single treatment session to provide long-lasting pain relief lasting up to three months.
-
ATX01: AlgoTherapeutix
ATX01 is an experimental topical treatment designed to relieve peripheral neuropathic pain, particularly in patients with Chemotherapy-Induced Peripheral Neuropathy (CIPN). It acts by blocking critical sodium channels involved in pain signaling, providing targeted relief to areas most affected by CIPN, such as the hands and feet.
Chemotherapy Induced Peripheral Neuropathy (CIPN) Pipeline Therapeutic Assessment
Chemotherapy Induced Peripheral Neuropathy (CIPN) Assessment by Product Type
• Mono
• Combination
• Mono/Combination
Chemotherapy Induced Peripheral Neuropathy (CIPN) By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Chemotherapy Induced Peripheral Neuropathy (CIPN) Assessment by Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Chemotherapy Induced Peripheral Neuropathy (CIPN) Assessment by Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Download sample pages to get an in-depth assessment of the emerging Chemotherapy Induced Peripheral Neuropathy (CIPN) therapies and key Chemotherapy Induced Peripheral Neuropathy (CIPN) companies
Table of Contents
1. Report Introduction
2. Executive Summary
3. Chemotherapy Induced Peripheral Neuropathy (CIPN) Current Treatment Patterns
4. Chemotherapy Induced Peripheral Neuropathy (CIPN) – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Chemotherapy Induced Peripheral Neuropathy (CIPN) Late-Stage Products (Phase-III)
7. Chemotherapy Induced Peripheral Neuropathy (CIPN) Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Chemotherapy Induced Peripheral Neuropathy (CIPN) Discontinued Products
13. Chemotherapy Induced Peripheral Neuropathy (CIPN) Product Profiles
14. Chemotherapy Induced Peripheral Neuropathy (CIPN) Key Companies
15. Chemotherapy Induced Peripheral Neuropathy (CIPN) Key Products
16. Dormant and Discontinued Products
17. Chemotherapy Induced Peripheral Neuropathy (CIPN) Unmet Needs
18. Chemotherapy Induced Peripheral Neuropathy (CIPN) Future Perspectives
19. Chemotherapy Induced Peripheral Neuropathy (CIPN) Analyst Review
20. Appendix
21. Report Methodology
Request the sample PDF to get detailed insights about the Chemotherapy Induced Peripheral Neuropathy (CIPN) pipeline reports offerings
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/